Yseop
WashedAI NativePrivateUpdated November 15, 2026A pre-GenAI natural language generation platform that has not kept pace with the market.
- Website
- yseop.com
- Founded
- 2007
- CEO
- Emmanuel Walckenaer
- HQ
- Paris, France
- Stage
- Private
- Revenue
- Not disclosed
- Total Funding
- $28M
- Employees
- 11-50
Executive Summary
Updated Nov 12, 2026
What they do
- Generative AI that drafts regulatory documents for pharma and biotech companies
- Automates clinical study reports, patient narratives, clinical summaries and CMC content
- Works inside Microsoft Word and Veeva Vault, built on Amazon Bedrock
Why it matters
- Customers reportedly include Eli Lilly, Novartis, GSK and AstraZeneca
- Mixes symbolic AI, machine learning and LLMs so outputs are traceable and auditable
- Says it generates over 27,000 reports a month, pointing to production use
Best fit
- Top-20 pharma medical writing teams with heavy clinical study report workloads
- Regulatory affairs groups that need faster submissions with outputs traceable to source data
- Life sciences companies whose writers already work in Word and Veeva Vault
Watch-outs
- Small vendor of roughly 140-150 staff facing IQVIA, Certara and Veeva
- Funding is modest; latest deal was €10M from Claret Capital
- Full one-click dossier automation is still a roadmap, not a shipped product
Products & Offerings
Yseop Copilot
Enterprise generative AI platform that drafts and checks clinical study reports, patient narratives, summaries and CMC documents inside Microsoft Word and Veeva Vault.
One-Click Dossier
Planned eCTD-aligned workflow combining live data integration, AI content generation and adaptive templates to automate regulatory submission documents end to end.
Financial reporting automation
Older natural language generation software that turns financial data into written reports for financial services clients.
Updated Nov 12, 2026
Yseop is a credible specialist in regulatory and medical writing for life sciences, with real deployments at major pharma companies and a product that has been in production since 2023. It deserves a structured evaluation against Certara CoAuthor, Narrativa and Peer AI, run as a pilot on your own clinical study reports and narratives that tests source traceability and how reviewer edits are handled. Before committing, check its financial resilience and roadmap, given its small size and the AI products that larger platforms such as Veeva are building.
Signal Provenance
Latest observation date and source for each signal category
| Signal Category | Last Updated | Source |
|---|---|---|
Funding Signals Last funding round, Funding stage | Nov 15, 2026 | Cited web research |
Hiring Velocity Headcount, Headcount growth | Nov 15, 2026 | Research agents (estimate) |
Technical Output Research papers, GitHub activity | Nov 13, 2026 | Hugging Face Hub + news feed + research agents |
News Sentiment News mentions, News sentiment | Nov 15, 2026 | Verified news feed |
Partnership Signals Enterprise partnerships, Distribution partners | Nov 15, 2026 | Research agents (estimate) |
Revenue Indicators ARR estimate, Revenue growth | Nov 15, 2026 | Research agents (estimate) |
Leadership Signals CEO tenure, Founder-led | Nov 15, 2026 | Research agents (estimate) |
Competitive Position Category rank, Market share | Nov 9, 2026 | Research agents (estimate) |
Why this Bluescore?
6 dimensions, each scored 0–10 against all 250 companies. Each adds its weight × score to the Bluescore — see methodology
Yseop scores below the AI250 median on every dimension. Its relative strength is Customer Adoption (5.2, 33rd percentile); its weakest area is Business Model & Revenue (2.5, 4th percentile).
In plain English
Yseop's Bluescore of 31.4 out of 100 is held back mostly by Business Model & Revenue, which scores 2.5 of 10 and sits at the 4th percentile among the AI250, with 15.8 points still left of its 21-point weight. Its strongest area is Customer Adoption at 5.2 of 10, though that only reaches the 33rd percentile, while Investment Momentum at 2.2 of 10 (12th percentile) also pulls it down. Business Model & Revenue and Product Depth each carry 21% weight and Product Depth scores 3.1 of 10, so improving Business Model & Revenue would move the overall score the most.
Written by AI from the scores below and checked against them; updated nightly.
Risks
Updated Nov 12, 2026